Oxaliplatin (NSC 266046)

For research use only. Not for use in humans.

目录号:S1224 别名: L-OHP, Eloxatin 中文名称:奥沙利铂

Oxaliplatin (NSC 266046) Chemical Structure

CAS No. 61825-94-3

Oxaliplatin (NSC 266046, L-OHP, Eloxatin)是一种DNA烷基化药物可以激活自噬。Oxaliplatin在RT4,TCCSUP,A2780,HT-29,U-373MG,U-87MG,SK-MEL-2,和 HT-144细胞中通过形成DNA加合物而抑制DNA合成。建议使用DMF溶解,现配现用。

规格 价格 库存 购买数量  
RMB 572.83 现货
RMB 1704.66 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Oxaliplatin (NSC 266046)发表文献132篇:

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Oxaliplatin (NSC 266046, L-OHP, Eloxatin)是一种DNA烷基化药物可以激活自噬。Oxaliplatin在RT4,TCCSUP,A2780,HT-29,U-373MG,U-87MG,SK-MEL-2,和 HT-144细胞中通过形成DNA加合物而抑制DNA合成。建议使用DMF溶解,现配现用。
特性 不建议使用DMSO溶解。[9]
靶点
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
体外研究

Oxaliplatin 主要作用机制是形成DNA交联剂而发挥作用。Oxaliplatin 诱导DNA一级和二级结构损伤而导致细胞凋亡。[1] Oxaliplatin 有效作用于人类黑色素瘤细胞系C32 和G361,IC50分别为0.98 mM 和0.14 mM。[2] Oxaliplatin有效抑制膀胱癌细胞系RT4 和 TCCSUP,卵巢癌细胞系A2780,结肠癌细胞系HT-29,胶质母细胞瘤细胞系U-373MG和U-87MG,和黑色素瘤细胞株SK-MEL-2和HT-144,IC50分别为11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM, 和 7.85 μM。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Caco2 NFnVR3JHfW6ldHnvckBCe3OjeR?= M36yPFMxNzFyMNMg{txO MWixOuKhcA>? MWfEUXNQ M1naVIFkfGm4YYTld{BPemZ{ MoLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NU[0NVUoRjJ2NUW2OFE2RC:jPh?=
Caco2  NF[xPJZHfW6ldHnvckBCe3OjeR?= NW\FfYJkOy9zMD:zNEDPxE1? M{O0TFE3KGh? NVzPcYVXTE2VTx?= NYXvcXJEcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQVvSNWMyNCCQUV:xMEBJVy1zLDDNVnAzNMLiYX7kUXJRO8LiZH;z[U1l\XCnbnTlcpRtgQ>? M2XsTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW2OFE2Lz5{NEW1OlQyPTxxYU6=
Caco2  MmnmSpVv[3Srb36gRZN{[Xl? M3r0XlMxyqEQvF2= NXHpTIg3OjRiaB?= NILvXWZFVVOR MnPWbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDIU{0yNCCDS2KxR{wh[W6mIF7RU|E> NHW1elA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1OlQyPSd-MkS1OVY1OTV:L3G+
SW620 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O0NFExNTdyIH3nM2w> MWeyOE81QC95MjDo NWr5RmtPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NFvNe2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0OlMxPSd-MkS2OFY{ODV:L3G+
SW480  Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe0PEBpyqB? NFq2TYFKSzVyPUKwMlghfWdxbVy= M33mflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{KwOlc2Lz5{NEeyNFY4PTxxYU6=
HCT116 MVTGeY5kfGmxbjDBd5NigQ>? MWmyM|UhyrWP NUTzR5p5OjRxNEigbC=> MY\zeZBxemW|c3XzJJN2en[rdnnuJI1TVkFiZYjwdoV{e2mxbh?= NX;ZfWFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlE1OTFpPkK0O|YyPDFzPD;hQi=>
HT-29 M3XDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;q[|htOcLizszN MUiwMVczKGh? NFfUVo1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? MoDQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnHb4EyyqEQvF2= NXe3[4RiOC15MjDo M4DaXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz Mnf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
HUVEC M3HKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFzLkOwxsDDucLiMT6wNkDPxE1? M4HCWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
HEK293 M4Tlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHqTWM2OD16LkiyxsDDucLiNT61PUDPxE1? NUjQZ2d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
HT-29 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PaeWlEPTB-NUCg{txO MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
HCT-116 M4SyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTZwMkVCpOKyyqB{Lkm3JO69VQ>? M3X1Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
MCF-7 MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTZTW9tUUN3ME2xOE4zPMLiwsJCpFEvQDJizszN MkHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
HepG2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TON2lEPTB;MUSuNlTDqMLzwrCxMlgzKM7:TR?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
A549 NYC5UGZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L0XWlEPTB;NUGuNFjDqMLzwrCxNE46PiEQvF2= NYPKc5RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
SGC7901 M4Lu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJzLkezxsDDucLiMz6wPEDPxE1? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
COC1 NEjPRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTR4LkKwxsDDucLiMz6xOEDPxE1? NFfFPGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO|Q1QCd-MkWzNFc1PDh:L3G+
HCT116  M1XFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHCO|IhcMLi Mli3TWM2OD14LkKzxtExNjd3INM1[{9uVA>? NEj5b289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NFY{OSd-MkWzOlA3OzF:L3G+
SW480 Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPyO|IhcMLi Mo[3TWM2OD1zMD63xtEzNjJ4INM1[{9uVA>? M{[4dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[wOlMyLz5{NUO2NFY{OTxxYU6=
MIAPaCa-2 NVqxUJN4TnWwY4Tpc44hSXO|YYm= M2D4NFI26oDLwsXN MXqyOE81QCCq MXXpcoR2[2W|IHPs[YF3[WenIH;mJHBCWlBuIHPhd5Bie2VvOTygZ4F{eGG|ZT24JIFv\CClYYPwZZNmNTQEoB?= M2rRfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
Panc-1 NV3uPW06TnWwY4Tpc44hSXO|YYm= MUWyOgKBkcL3TR?= M{DvOFI1NzR6IHi= M1\5Solv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg NWnvbnVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
MIAPaCa-2 M4XRNGFxd3C2b4Ppd{BCe3OjeR?= NWjq[pBjOjYkgJpCuW0> M164VVI1KGh? NWe1XYJWcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= Mk\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
Panc-1 NUmwSXNQSXCxcITvd4l{KEG|c3H5 M2PGZ|I26oDLwsXN NEPNc4IzPCCq M2HaeIlv\HWlZYOgZZBweHSxc3nzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? MlLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
HPDE M2rPWmNmdGxiVnnhZoltcXS7IFHzd4F6 MXWyOU82OCEQvF2= MXyyOE81QCCq MVTpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> MmrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
SW1990 NGDrS3JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MU[yOU82OCEQvF2= MonLNlQwPDhiaB?= Mn;1bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC NIXOUZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OFkyPCd-MkW0OFQ6OTR:L3G+
MIAPaCa-2 MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NE\LNYczPS93MDFOwG0> NITEWlIzPC92ODDo MXrpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> M1m0OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
Panc-1 M4TkcmNmdGxiVnnhZoltcXS7IFHzd4F6 M3;VcFI2NzVyIN88US=> MUiyOE81QCCq MmjRbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC NYfjbWpnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
A549/CDDP M17vPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPiTWM2OD1zOD62JOKyKDFwMjFOwG0> MmLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkWyOFMoRjJ3NkK1NlQ{RC:jPh?=
A549 NXPae4lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDKTWM2OD13LkigxtEhOC54IN88US=> NVLLcZd1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlUzPDNpPkK1OlI2OjR|PD;hQi=>
SW480 NUXESlN[TnWwY4Tpc44hSXO|YYm= MYWxNQKBkcL3Zz;tcC=> NXraVoZMOjUkgJno NU\kUGZQ\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4 MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUSyNEc,OjV5NEm0NlA9N2F-
SW620 M3PtdmZ2dmO2aX;uJGF{e2G7 MYOxNQKBkcL3Zz;tcC=> NWXUcFA6OjUkgJno MV3lcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? MlzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEm0NlAoRjJ3N{S5OFIxRC:jPh?=
SW480 MVHGeY5kfGmxbjDBd5NigQ>? M{ThWFEx6oDLwsXnM41t NGG2SmczPOLCiXi= NHXP[npqdmO{ZXHz[ZMhVEN|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUSyNEc,OjV5NEm0NlA9N2F-
SW620 MUHGeY5kfGmxbjDBd5NigQ>? MmDJNVDjiIoEtXevcYw> M1i3[|I16oDLaB?= NWfodHVmcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= NEfzWow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
HT-29 MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC3VIhbUUN3ME21MlIzKM7:TR?= NFvjdYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
SNU-175 Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3lPVdSUUN3ME2xMlUyKM7:TR?= MkmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O|koRjJ3N{[xOFc6RC:jPh?=
COLO-320DM NVziXIUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTVwM{ig{txO NFLi[pM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
DLD-1 M2nvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu2dZVKSzVyPUiuOlUh|ryP M2W1fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
DiFi Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD5TWM2OD1zMD65OUDPxE1? MmnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O|koRjJ3N{[xOFc6RC:jPh?=
HCT-15 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT2ZYhMUUN3ME24MlY1KM7:TR?= NHSzPHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
SCM-1 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{SzNWlEPTB;MUeuOUDPxE1? M2HSVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{i5NFU4Lz5{NUe4PVA2PzxxYU6=
TMK-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XG[GlEPTB;MkKuOkDPxE1? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd6OUC1O{c,OjV5OEmwOVc9N2F-
MKN-45 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjsOZVKSzVyPUG0MlAh|ryP M1v1eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{i5NFU4Lz5{NUe4PVA2PzxxYU6=
AGS NY\TWmNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL3N3ZtUUN3ME2xNE43KM7:TR?= NYr1fFhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PFkxPTdpPkK1O|g6ODV5PD;hQi=>
S3 Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXNTWM2OD13Mz61JOKyKDFwNTFOwG0> NYjBRY9qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFExODdpPkK1PFAyODB5PD;hQi=>
SiHa NVHBUpJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTETWM2OD1yLkigxtEhOC5zIN88US=> NFe2R2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwNVAxPyd-MkW4NFExODd:L3G+
HT-29 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qzU2lEPTB;M{WuOkDPxE1? NYD3V3pDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFMxQDVpPkK2NFA{ODh3PD;hQi=>
DLD-1 M{fnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;neGlEPTB;M{KuNkDPxE1? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByM{C4OUc,OjZyMEOwPFU9N2F-
HT29 M{TDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7UTGtKSzVyPU[zJO69VSEEsTCxPC=> M{XrPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC0NFg1Lz5{NkCwOFA5PDxxYU6=
MC38 NGq3XZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljETWM2OD1{MzFOwG0hyrFiMh?= MoThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMESwPFQoRjJ4MEC0NFg1RC:jPh?=
SW620 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nFTmlEPTB;Mz62PEDPxE1? NGG3RVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
SW480 M323Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7lRohKSzVyPUKuPFYh|ryP NGexepA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
RKO Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Pp[mlEPTB;MT6yN{DPxE1? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
LoVo MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3INVZKSzVyPUGuNkDPxE1? M{DCeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
KM12 NYeyd2JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPEeGl{UUN3ME20MlM4KM7:TR?= NYnQcJhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
HCT116p53- MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwMEig{txO NH7rW2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
HCT116 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwMESg{txO NFPOWJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
HCT15 NIDjc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PNOmlEPTB;MT60N{DPxE1? M{TMVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
HT29 M4[1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP4TWM2OD1{Lk[5JO69VQ>? M1vLNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
DLD1 NX\GZYRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX4[IlFUUN3ME2yMlAyKM7:TR?= M3SyWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
Colo205 NIH2OmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jlZ2lEPTB;Mz6zN{DPxE1? MlO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
BE Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTNwM{Og{txO MnXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
CT26  MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NW\n[mVXPCCvTR?= NETWUY01QCCqwrC= MlPL[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITvJFU{NjJn NHfoNFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|AyOid-Mk[xN|cxOTJ:L3G+
CT26  NH3GOlBHfW6ldHnvckBCe3OjeR?= MWS0JI1O NG\NNII1QCCqwrC= NWHObGxScW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuczDv[kBifXSxcHjh[5kuemWuYYTl[EBxem:2ZXnud{whe3WlaDDhd{BNSzNvSVmsJGJm[2yrbkGgZY5lKEGWR{W= M2n1c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NFEzLz5{NkGzO|AyOjxxYU6=
CT26  MULGeY5kfGmxbjDBd5NigQ>? NXfMUIRiPCCvTR?= NXfi[Wl2PDhiaNMg MYfpcoR2[2W|IHH1eI9xcGGpeR?= M4SwclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NFEzLz5{NkGzO|AyOjxxYU6=
SK-OV-3 NVvBb5hMTnWwY4Tpc44hSXO|YYm= NXy5N2s4PTBizszNxsA> NHjyWWo1QCCqwrC= NEHN[VFxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> NVvle5JXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
OVCAR-5 MVnGeY5kfGmxbjDBd5NigQ>? M{Tj[FIxKM7:TdMg MnrHNlRp MX\wdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= NX3LOVFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
PA-1 NGH6PZNHfW6ldHnvckBCe3OjeR?= NWXTR3k6OTBizszNxsA> MnfBNlRp M4DSbJBzd22xdHXzJJNmdnOrdHn2bZR6KG:oIH;2ZZJq[W5iY3HyZ4lvd22jIITvJG5MKGOnbHytcYVlcWG2ZXSgZ5l1d2y7c3nz NEjWV4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
SK-OV-3 NY\uZW1wTnWwY4Tpc44hSXO|YYm= M1\XSlUxKM7:TR?= MnfyPVYhcA>? NH20WY12eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? NUP3W4lZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
OVCAR-5 MULGeY5kfGmxbjDBd5NigQ>? MXyzNEDPxE1? MWi0PIg> NV;W[JZXfXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| NHvQXZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
PA-1 M1jCNGZ2dmO2aX;uJGF{e2G7 NGPwcYQyOCEQvF5CpC=> MYq0PIg> M{D1VZVxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>? Mk\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
SK-OV-3 NEX6e2FHfW6ldHnvckBCe3OjeR?= M33iVFUxKM7:TR?= NXjafVJYQTZiaB?= NGnLSHh1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> M1rOU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
OVCAR-5 MmfySpVv[3Srb36gRZN{[Xl? MnHuN|Ah|ryP MoTBOFhp MlzpeJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
PA-1 NIHZdmpHfW6ldHnvckBCe3OjeR?= NV\meXBIOTBizszNxsA> NIHw[XUzPGh? NGHDZWd1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> NGe0c5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
SK-OV-3 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlTrNE0yODBizszN M1r4NFI1NzR6L{eyJIg> NGDnWZdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NFfucIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
OVCAR-5 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUntSIFqOC14MDFOwG0> NXPXN5FCOjRxNEivO|IhcA>? MXPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NHey[YM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
PA-1 MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NH[2UVUxNTJyIN88US=> NW\ZO4k1OjRxNEigbC=> NXL0fXNUcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M4PSO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
HCT116 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwNEJCpOKyyqByLkCyJO69VQ>? NEDXXG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG0PFU6Pid-Mk[xOFg2QTZ:L3G+
HT29 NIjPVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwOElCpOKyyqByLkKg{txO MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF2OEW5Okc,OjZzNEi1PVY9N2F-
SNU-387 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ3wrFCteKhOi55IN88US=> M2rBNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[wOFI6Lz5{NkG2NFQzQTxxYU6=
SNU-475 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr1[XlYUUN3MP-8olMxKM7:TR?= NEfMe3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
Hep-G2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7DSmRKSzVyPUGzMlHDqMLzwrCxMlYh|ryP NF2wSYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
SNU-398 M{TXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XIWWlEPTB;Nj61xsDDucLiMT6xJO69VQ>? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4MESyPUc,OjZzNkC0Nlk9N2F-
LoVo  M{P0N2Z2dmO2aX;uJGF{e2G7 MkfZNU82KM7:TR?= MmnVNlQwPDhiaB?= MnribY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?= NEHqRlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKwPFUzOyd-Mk[yNFg2OjN:L3G+
HCT116 p53+/+ MWrGeY5kfGmxbjDBd5NigQ>? MXmxM|Uh|ryP NGDNd|QzPC92ODDo MULpcoR2[2W|IITyZY5{[3KrcITpc45idCC{ZYDy[ZN{cW:wIH;mJGRWXC2Q MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJyOEWyN{c,OjZ{MEi1NlM9N2F-
MDA-MB-231 M3HmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJ|LkGgxtEhOC5zIN88US=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJzMUW5NUc,OjZ{MUG1PVE9N2F-
MCF-7 Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF3LkSgxtEhOC5|IN88US=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJzMUW5NUc,OjZ{MUG1PVE9N2F-
SK-BR-3 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXhTWM2OD1|MT6wJOKyKDBwMTFOwG0> Mn\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUG1PVEoRjJ4MkGxOVkyRC:jPh?=
LoVo MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly4OFghcMLi MV\JR|UxRTl2LkizJO69VQ>? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ4OUe1PUc,OjZ{Nkm3OVk9N2F-
HCT116 MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe0PEBpyqB? NHfOWHpKSzVyPUGxMlg3KM7:TR?= Mn;RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{Nkm3OVkoRjJ4Mk[5O|U6RC:jPh?=
SW480 M{Sz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3lcItCPDhiaNMg MYLJR|UxRTFwOEeg{txO NGLMbWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK2PVc2QSd-Mk[yOlk4PTl:L3G+
CaES-17 MlL6R5l1d3SxeHnjbZR6KEG|c3H5 Moj2NQKBmzF4MNMg{txO M{n5VFQ5yqCq NFnwTlVKSzVyPUWuOeKhyrIEoECuNkDPxE1? NFTENG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS3OFY6Oyd-Mk[0O|Q3QTN:L3G+
HKESC-2 NFTXb4JEgXSxdH;4bYNqfHliQYPzZZk> MWSw5qCUOTZywrFOwG0> NXP3T|NWPDkEoHi= NI\ldldKSzVyPUWuPOKhyrIEoECuOUDPxE1? M1jZU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEe0Olk{Lz5{NkS3OFY6OzxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
VEGFR-1 / NRP-1 ; 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. 

p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min.

p-Src(Y418) / p-FAK(Y861) ; 

PubMed: 19383922     


Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘瘿⟸෕ᾰƌ෕Ð㺣痖帉痖Ѐ

18790786 19383922
Immunofluorescence
E-cadherin / Vimentin; 

PubMed: 30787271     


Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells.

ATXN2L / G3BP1; 

PubMed: 30787271     


Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules. 

30787271
Growth inhibition assay
Cell viability ; 

PubMed: 28339092     


Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations. 

28339092
体内研究

Oxaliplatin按10 mg/kg 剂量每周腹腔注射给药携带肝癌HCCLM3肿瘤的裸鼠,显著降低肿瘤体积和凋亡指数。[6] Oxaliplatin 按5mg/kg剂量在实验第1, 5 和 9天静脉注射给药,有效作用于T型白血病淋巴瘤L40 AKR,T/C为1.77。Oxaliplatin也有效作用于脑内移植的L1210白血病, MA 16-C移植瘤, B16黑色素瘤移植瘤, Lewis肺癌移植瘤,和C26 结肠癌移植瘤。[7]Oxaliplatin作用于小鼠,诱导退行性神经转导降低。[8]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[4]

- 合并
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 和 HT-144 细胞系
  • Concentrations: ~100 μM
  • Incubation Time: 48 小时
  • Method:

    使用 sulforhodamine-B 显微培养比色测定法进行细胞毒性研究。实验第0天细胞接种在96孔板上,实验第1天使用Oxaliplatin 处理细胞,48小时后,进行sulforhodamine-B 检测。除了添加Oxaliplatin和最终实验测定期间,实验全程在37°C 下含5% CO2 和 100% 相对湿度的环境下进行。检测到细胞的初始数目为每孔2-20 × 103个细胞/50 nL。接种和药物处理期间细胞数目如下(a)检测时对照组细胞仍处于对数期生长;(b)检测时未处理的对照组细胞最大吸光度为1.0〜1.5;(c)用药物处理期间细胞经过2倍以上倍增。每种浓度放置8孔。使用Biotek仪器EL309酶标仪与IBM PC-兼容型计算机在570 和/或 540 nm处测定。通过计算机程序DATALOG将实验数据传输且转化为LOTUS 1-2-3格式,通过比较实验组和对照组计算存活分数。


    (Only for Reference)
动物实验:

[6]

- 合并
  • Animal Models: 携带人类肝癌移植瘤HCCLM3的小鼠
  • Dosages: 10 mg/kg
  • Administration: 每周腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 Water 3 mg/mL warmed (7.55 mM)
DMF Insoluble
Ethanol ''0.01 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 397.29
化学式

C8H14N2O4Pt

CAS号 61825-94-3
储存条件 2年 4°C(避光) 粉末
别名 L-OHP, Eloxatin

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05025826 Not yet recruiting Other: Phycocare|Other: Placebo Metastatic Gastric Cancer Nantes University Hospital|Algosource November 5 2021 Not Applicable
NCT05031975 Not yet recruiting Drug: Irinotecan|Drug: Temozolomide Colorectal Cancer Fondazione IRCCS Istituto Nazionale dei Tumori Milano November 1 2021 Phase 2
NCT04944550 Recruiting -- Upper Urinary Tract Urothelial Carcinoma|Nephroureterectomy|Tumor|Xenograft Model Centre Hospitalier Universitaire de Nīmes|INSERM U1194 Institut de Recherche en Cancérologie de Montpellier Campus Val d''Aurelle 34298 Montpellier cedex 5 March 1 2021 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • 回答:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

免费分装抑制剂

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046)供应商 | 采购Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046)价格 | Oxaliplatin (NSC 266046)生产 | 订购Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID